Singapore markets open in 3 hours 32 minutes
  • Straits Times Index

    +24.67 (+0.76%)
  • S&P 500

    +3.82 (+0.08%)
  • Dow

    -201.79 (-0.56%)
  • Nasdaq

    +86.95 (+0.59%)

    -436.40 (-1.00%)
  • CMC Crypto 200

    +12.03 (+1.17%)
  • FTSE 100

    -20.90 (-0.28%)
  • Gold

    +0.80 (+0.04%)
  • Crude Oil

    +0.45 (+0.54%)
  • 10-Yr Bond

    +0.0610 (+3.57%)
  • Nikkei

    -364.82 (-1.28%)
  • Hang Seng

    -46.48 (-0.19%)
  • FTSE Bursa Malaysia

    -14.18 (-0.90%)
  • Jakarta Composite Index

    +35.04 (+0.53%)
  • PSE Index

    -46.41 (-0.64%)

Canadian Blood Services Awards Takeda Canada Three-Year Tender for Hemophilia treatment ADYNOVATE®

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

TORONTO, Nov. 17, 2021 /CNW/ - Takeda Canada is pleased to announce that Canadian Blood Services (CBS) has awarded a three-year tender for ADYNOVATE®i [Antihemophilic Factor (Recombinant) PEGgylated] as part of its request for proposal for recombinant Factor VIII Standard Half-Life (SHL) process as part of its formulary product mix. The three-year term is the second consecutive time Takeda has won the CBS tender for ADYNOVATE®, which includes two 1-year option years.

Takeda Canada Inc. Logo (CNW Group/Takeda Canada Inc.)
Takeda Canada Inc. Logo (CNW Group/Takeda Canada Inc.)

"Being able to continue to provide Canadian hemophilia patients with this important treatment option is a tremendous source of pride for Takeda," said Rute Fernandes, General Manger, Takeda Canada. "Adopting a holistic approach that incorporates real world evidence, delivers personalized care, and support services that address the needs of patients beyond their treatment, underscores Takeda's commitment to patients and providing value to the healthcare system. We look forward to continuing our relationship with Canadian Blood Services, and through it, being able to extend the benefits of ADYNOVATE® as well as the support services we are committed to making available for patients."

As part of the tendering process in response to the Canadian Blood Services' value-based criteria, Takeda presented a model that transitioned from one that was strictly price-based to one that included value-based criteria. This transition represents a significant milestone towards a more sustainable procurement model, and ultimately a better, more holistic approach to supporting the hemophilia A community.

ADYNOVATE®ii is a pegylated recombinant Antihemophilic factor (ADVATE®iii) and is indicated in patients with hemophilia A (congenital factor VII deficiency) for: control and prevention of bleeding episodes; prophylaxis to prevent or reduce the frequency of bleeding episodes; perioperative management.

About Takeda Canada Inc.
Takeda Canada Inc. is the Canadian marketing and sales organization of Takeda Pharmaceutical Company Limited, headquartered in Japan. Takeda Pharmaceutical Company Limited (TSE:4502)(NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Rare Diseases and Neuroscience. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.

Additional information about Takeda Canada is available at

SOURCE Takeda Canada Inc.


View original content to download multimedia:

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting